Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells
Open accessAbstract
Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) combination safely cures fatal acute promyelocytic leukemia, but their mechanisms of action and efficacy are not fully understood. ATRA inhibits leukemia, breast, and liver cancer by targeting isomerase Pin1, a master regulator of oncogenic signaling networks. Here we show that ATO targets Pin1 and cooperates with ATRA to exert potent anticancer activity. ATO inhibits and degrades Pin1, and suppresses its oncogenic function by noncovalent binding to Pin1’s active site. ATRA increases cellular ATO uptake through upregulating aquaporin-9. ATO and ATRA, at clinically safe doses, cooperatively ablate Pin1 to block numerous cancer-driving pathways and inhibit the growth of triple-negative breast cancer cells and tumor-initiating cells in cell and animal models including patient-derived orthotopic xenografts, like Pin1 knockout, which is substantiated by comprehensive protein and microRNA analyses. Thus, synergistic targeting of Pin1 by ATO and ATRA offers an attractive approach to combating breast and other cancers.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
RA promoted terminal differentiation of leukemic cells while reducing their proliferation.
“RA promoted terminal differentiation of leukemic cells while reducing their proliferation.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [11]
The antitumoral activity of RA (enhanced by cooperation with arsenic trioxide) was due to inhibition and degradation of prolyl isomerase Pin1, which has a critical role in coordinating multiple phosphorylation events during oncogenesis.
“The antitumoral activity of RA (enhanced by cooperation with arsenic trioxide)11 was due to inhibition and degradation of prolyl isomerase Pin1, which has a critical role in coordinating multiple phosphorylation events during oncogenesis12.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
<i>Phaser</i> crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · see citing works
MicroRNA expression profiles classify human cancers
Lü, J., Getz, G. A., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,497 · see citing works
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M. W., Reinhard, F., Zhang, C. C., Shipitsin, M. V., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,679 · see citing works
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741 · see citing works
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,719 · see citing works
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · see citing works
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302 · see citing works
The CCPN data model for NMR spectroscopy: Development of a software pipeline
Vranken, W., Boucher, W., Stevens, T. J., Fogh, R. H., Pajon, A., Llinás, M., Ulrich, E. L., Markley, J. L., Ionides, J., & Laue, E. D. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20449 · Cited by 3,222 · see citing works
Integration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,494 · see citing works
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765 · see citing works
Jordan, C. T., Guzmán, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,708 · see citing works
Mechanisms of specificity in protein phosphorylation
Ubersax, J. A., & Ferrell Jr, J. E. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2203 · Cited by 1,451 · see citing works
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,283 · see citing works
Triple-negative breast cancer: therapeutic options
Cleator, S. J., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 884 · see citing works
Chen, G.-Q., Zhu, J., Shi, X., Ni, J., Zhong, H., Si, G., Jin, X., Tang, W., Li, X., Xong, S., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1052.1052 · Cited by 863 · see citing works
Shen, S., Li, X., Cullen, W., Weinfeld, M., & Le, X. C. (2013) · Chemical Reviews · doi:10.1021/cr300015c · Cited by 822 · see citing works
Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML
Zhang, X., Yan, X.-J., Zhou, Z., Yang, F., Wu, Z., Sun, H., Liang, W., Song, A., Lallemand-Breitenbach, V., Jeanne, M., et al. (2010) · Science · doi:10.1126/science.1183424 · Cited by 785 · see citing works
Yaffe, M. B., Schutkowski, M., Shen, M., Zhou, X. Z., Stukenberg, P. T., Rahfeld, J., Xu, J., Kuang, J., Kirschner, M. W., Fischer, G. S., et al. (1997) · Science · doi:10.1126/science.278.5345.1957 · Cited by 770 · see citing works
Self-citationRanganathan, R., Lu, K. P., Hunter, T. R., & Noel, J. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80273-1 · Cited by 703 · see citing works
Self-citationProlyl cis-trans isomerization as a molecular timer
Lu, K. P., Finn, G., Lee, T. H., & Nicholson, L. K. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.35 · Cited by 655 · see citing works
Self-citationRyo, A., Suizu, F., Yoshida, Y., Perrem, K., Liou, Y., Wulf, G. M., Rottapel, R. K., Yamaoka, S., & Lu, K. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00490-8 · Cited by 632 · see citing works
Self-citationWulf, G. M., Ryo, A., Wulf, G. G., Lee, S. W., Niu, T., Petkova, V., & Lu, K. P. (2001) · The EMBO Journal · doi:10.1093/emboj/20.13.3459 · Cited by 529 · see citing works
Self-citationArsenite transport by mammalian aquaglyceroporins AQP7 and AQP9
Liu, Z., Shen, J., Carbrey, J. M., Mukhopadhyay, R., Agre, P., & Rosen, B. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092131899 · Cited by 505 · see citing works
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
de Thé, H., & Zhu, C. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2943 · Cited by 490 · see citing works
Ryo, A., Nakamura, M., Wulf, G. M., Liou, Y.-C., & Lu, K. P. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-793 · Cited by 467 · see citing works
Self-citationAntibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy
Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.-H., Yao, Y., Lin, Y.-M., Driver, J. A., Sun, Y., et al. (2015) · Nature · doi:10.1038/nature14658 · Cited by 445 · see citing works
Self-citationRole of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration
Liou, Y., Sun, A., Ryo, A., Zhou, X. Z., Yu, Z.-X., Huang, H.-K., Uchida, T., Bronson, R. T., Bing, G., Li, X., et al. (2003) · Nature · doi:10.1038/nature01832 · Cited by 436 · see citing works
Self-citationDilda, P. J., & Hogg, P. J. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.05.001 · Cited by 389 · see citing works
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Nasr, R., Guillemin, M.-C., Ferhi, O., Soilihi, H., Pérès, L., Berthier, C., Rousselot, P. H., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1891 · Cited by 354 · see citing works
Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes
Liou, Y.-C., Ryo, A., Huang, H.-K., Lu, P., Bronson, R. T., Fujimori, F., Uchida, T., Hunter, T. R., & Lu, K. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.032404099 · Cited by 338 · see citing works
Self-citationPML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3
Jeanne, M., Lallemand-Breitenbach, V., Ferhi, O., Koken, M. H. M., Bras, M. L., Duffort, S., Pérès, L., Berthier, C., Soilihi, H., Raught, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.003 · Cited by 332 · see citing works
How acute promyelocytic leukaemia revived arsenic
Zhu, J., Chen, Z., Lallemand-Breitenbach, V., & de Thé, H. (2002) · Nature reviews. Cancer · doi:10.1038/nrc887 · Cited by 324 · see citing works
Cancer genomics: one cell at a time
Navin, N. E. (2014) · Genome biology · doi:10.1186/s13059-014-0452-9 · Cited by 311 · see citing works
Lallemand-Breitenbach, V., Guillemin, M.-C., Janin, A., Daniel, M., Degos, L., Kogan, S. C., Bishop, J. M., & de Thé, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1043 · Cited by 306 · see citing works
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Girardini, J. E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, V., Jordan, L. B., Quinlan, P., Thompson, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.004 · Cited by 283 · see citing works
Wei, S., Kozono, S., Kats, L., Nechama, M., Li, W., Guarnerio, J., Luo, M., You, M.-H., Yao, Y., Kondo, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3839 · Cited by 272 · see citing works
Self-citationThe isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target
Zhou, X. Z., & Lu, K. P. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.49 · Cited by 269 · see citing works
Self-citationNakamura, K., Greenwood, A., Binder, L. I., Bigio, E. H., Denial, S., Nicholson, L. K., Zhou, X. Z., & Lu, K. P. (2012) · Cell · doi:10.1016/j.cell.2012.02.016 · Cited by 255 · see citing works
Self-citationPIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells
Ryo, A., Liou, Y.-C., Wulf, G. M., Nakamura, M., Lee, S. W., & Lu, K. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5281-5295.2002 · Cited by 254 · see citing works
Self-citationArsenic trioxide, a therapeutic agent for APL
Zhang, T.-D., Chen, G., Wang, Z., Wang, Z., Chen, S., & Chen, Z. (2001) · Oncogene · doi:10.1038/sj.onc.1204762 · Cited by 231 · see citing works
DeRose, Y. S., Gligorich, K. M., Wang, G., Georgelas, A., Bowman, P., Courdy, S., Welm, A. L., & Welm, B. E. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1423s60 · Cited by 227 · see citing works
Connolly, R. M., Nguyen, N. K., & Sukumar, S. V. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3175 · Cited by 211 · see citing works
Prolyl isomerase Pin1 in cancer
Lu, Z., & Hunter, T. R. (2014) · Cell Research · doi:10.1038/cr.2014.109 · Cited by 203 · see citing works
Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism
Langenfeld, J. E., Kiyokawa, H., Sekula, D., Boyle, J., & Dmitrovsky, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12070 · Cited by 202 · see citing works
Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis
Wulf, G. M., Garg, P., Liou, Y., Iglehart, D. J., & Lu, K. P. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600323 · Cited by 199 · see citing works
Self-citationProlyl‐isomerase Pin1 controls normal and cancer stem cells of the breast
Rustighi, A., Zannini, A., Tiberi, L., Sommaggio, R., Piazza, S., Sorrentino, G., Nuzzo, S., Tuscano, A., Eterno, V., Benvenuti, F., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302909 · Cited by 156 · see citing works
Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer.
Smith, M. A., Adamson, P. C., Balis, F. M., Feusner, J. H., Aronson, L., Murphy, R. F., Horowitz, M. E., Reaman, G. H., Hammond, G. D., & FENTON, R. M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1666 · Cited by 151 · see citing works
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action
Campaner, E., Rustighi, A., Zannini, A., Cristiani, A., Piazza, S., Ciani, Y., Kalid, O., Golan, G., Baloglu, E., Shacham, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15772 · Cited by 151 · see citing works
Min, S. H., Lau, A. W., Lee, T. H., Inuzuka, H., Wei, S., Huang, P., Shaik, S., Lee, D. Y., Finn, G., Balaštík, M., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.04.012 · Cited by 146 · see citing works
Self-citationERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5
Sun, H., Cui, R., Zhou, J., Teng, K., Hsiao, Y., Nakanishi, K., Fassan, M., Luo, Z., Shi, G., Tili, E., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.001 · Cited by 143 · see citing works
dos Santos, G. A., Kats, L. M., & Pandolfi, P. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131121 · Cited by 141 · see citing works
Epidemiology of chronic disease related to arsenic in Argentina: A systematic review
Bardach, A. E., Ciapponi, A., Soto, N., Chaparro, M., Calderón, M., Briatore, A., Cadoppi, N., Tassara, R., & Litter, M. I. (2015) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2015.08.070 · Cited by 140 · see citing works
Farrell, A. S., Pelz, C., Wang, X., Daniel, C. J., Wang, Z., Su, Y., Janghorban, M., Zhang, X., Morgan, C. W., Impey, S., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01455-12 · Cited by 140 · see citing works
Leung, J., Pang, A. W. K., Yuen, W.-H., Kwong, Y., & Tse, E. (2006) · Blood · doi:10.1182/blood-2006-04-019588 · Cited by 130 · see citing works
Arrieta, O. G., la Rosa, C. H. G.-D., Aréchaga-Ocampo, E., Villanueva-Rodríguez, G., Cerón-Lizárraga, T., Martínez-Barrera, L. M., Vázquez-Manríquez, M. E., Ríos-Trejo, M. Á., Álvarez-Avitia, M. Á., Hernández‐Pedro, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6452 · Cited by 125 · see citing works
Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics
Lu, K. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00218-6 · Cited by 123 · see citing works
Self-citationFox, E., Razzouk, B. I., Widemann, B. C., Xiao, S., O'Brien, M., Goodspeed, W. J., Reaman, G. H., Blaney, S. M., Murgo, A. J., Balis, F. M., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107839 · Cited by 119 · see citing works
Suizu, F., Ryo, A., Wulf, G. M., Lim, J., & Lu, K. P. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1463-1479.2006 · Cited by 117 · see citing works
Self-citationSheng, N., Xie, Z., Wang, C., Bai, G., Zhang, K., Zhu, Q., Song, J., Guillemot, F., Chen, Y., Lin, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009244107 · Cited by 106 · see citing works
Self-citationPin1 inhibitors: Pitfalls, progress and cellular pharmacology
Moore, J. D., & Potter, A. J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.088 · Cited by 105 · see citing works
Nakano, A., Koinuma, D., Miyazawa, K., Uchida, T., Saitoh, M., Kawabata, M., Hanai, J.-I., Akiyama, H., Abe, M., Miyazono, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804659200 · Cited by 103 · see citing works
Liao, Y., Wei, Y., Zhou, X., Yang, J. Y., Dai, C., Chen, Y. J., Agarwal, N., Sarbassov, D. D., Shi, D., Yu, D., et al. (2009) · Oncogene · doi:10.1038/onc.2009.98 · Cited by 94 · see citing works
Self-citationThe Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation
Luo, M., Gong, C., Chen, C.-H., Hu, H., Huang, P., Zheng, M., Yao, Y., Wei, S., Wulf, G. M., Lieberman, J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.002 · Cited by 89 · see citing works
Self-citationAblain, J., Leiva, M., Pérès, L., Fonsart, J., Anthony, E., & de Thé, H. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20122337 · Cited by 87 · see citing works
Nechama, M., Kwon, J., Wei, S., Tun-Kyi, A., Welner, R. S., Ben‐Dov, I. Z., Arredouani, M. S., Asara, J. M., Chen, C.-H., Tsai, C.-Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03886-6 · Cited by 86 · see citing works
Self-citationLuo, M.-L., Gong, C., Chen, C.-H., Lee, D. Y., Hu, H., Huang, P., Yao, Y., Guo, W., Reinhardt, F., Wulf, G. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2785 · Cited by 85 · see citing works
Self-citationPhase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
Budd, G. T., Adamson, P. C., Gupta, M. K., Homayoun, P., Sandstrom, S. K., Murphy, R. F., McLain, D., Tuason, L. J., Peereboom, D. M., Bukowski, R. M., et al. (1998) · PubMed · Cited by 84 · see citing works
Arsenic compounds: revived ancient remedies in the fight against human malignancies
Liu, J., Zhou, G., Chen, S., & Zhu, C. H. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.01.015 · Cited by 78 · see citing works
Yang, D., Luo, W., Wang, J., Zheng, M., Liao, X., Zhang, N., Lu, W., Wang, L., Chen, A., Wu, W., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.031 · Cited by 69 · see citing works
Self-citationTakahashi, K., Akiyama, H., Shimazaki, K. I., Uchida, C., Akiyama-Okunuki, H., Tomita, M., Fukumoto, M., & Uchida, T. (2006) · Oncogene · doi:10.1038/sj.onc.1210153 · Cited by 64 · see citing works
Paulo, J. A., Gaun, A., & Gygi, S. P. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00398 · Cited by 58 · see citing works
NMR Methods for Studying Protein–Protein Interactions Involved in Translation Initiation
Marintchev, A., Frueh, D. P., & Wagner, G. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)30012-8 · Cited by 57 · see citing works
Liao, X.-H., Zhang, A. L., Zheng, M., Li, M.-Q., Chen, C. P., Xu, H., Chu, Q., Yang, D., Lu, W., Tsai, T., et al. (2017) · Scientific Reports · doi:10.1038/srep43639 · Cited by 48 · see citing works
Self-citationRapid Reduction in Breast Cancer Mortality With Inorganic Arsenic in Drinking Water
Smith, A. H., Marshall, G., Yuan, Y., Steinmaus, C., Liaw, J., Smith, M. T., Wood, L., Heirich, M. S., Fritzemeier, R., Pegram, M. D., et al. (2014) · EBioMedicine · doi:10.1016/j.ebiom.2014.10.005 · Cited by 46 · see citing works
Zheng, M., Xu, H., Liao, X., Chen, C. P., Zhang, A. L., Lu, W., Wang, L., Yang, D., Wang, J., Liu, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15967 · Cited by 40 · see citing works
Self-citationPin1 is required for sustained B cell proliferation upon oncogenic activation of Myc
D’Artista, L., Bisso, A., Piontini, A., Doni, M., Verrecchia, A., Kress, T. R., Morelli, M. J., Sal, G. D., Amati, B. B., & Campaner, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7846 · Cited by 39 · see citing works
Lian, X., Lin, Y., Kozono, S., Herbert, M. K., Li, X., Yuan, X., Guo, J., Guo, Y., Tang, M., Lin, J. L., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0611-7 · Cited by 33 · see citing works
Self-citationPin1‐Targeted Therapy for Systemic Lupus Erythematosus
Wei, S., Yoshida, N., Finn, G., Kozono, S., Nechama, M., Kyttaris, V. C., Zhou, X. Z., Tsokos, G. C., & Lu, K. P. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39741 · Cited by 31 · see citing works
Self-citationCribbes, S., Kessel, S. L., McMenemy, S., Qiu, J., & Chan, L. L. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217689884 · Cited by 29 · see citing works
The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections
Wang, J., Liao, X., Zheng, M., Yang, D., Zhou, X. Z. T., Liu, H.-H., & Lu, K. P. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666161124103654 · Cited by 6 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Sal, G. D. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 779 · see citing works
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Koikawa, K., Kibe, S., Suizu, F., Sekino, N., Kim, N., Manz, T. D., Pinch, B. J., Akshinthala, D., Verma, A., Gaglia, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.020 · Cited by 235 · see citing works
Self-citationSulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo
Dubiella, C., Pinch, B. J., Koikawa, K., Zaidman, D., Poon, E., Manz, T. D., Nabet, B., He, S., Resnick, E., Rogel, A., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00786-7 · Cited by 161 · see citing works
Self-citationChuang, L. I. U., Sun, S., Feng, Q., Wu, G., Wu, Y., Kong, N., Yu, Z., Yao, J., Zhang, X., Chen, W., et al. (2021) · Advanced Materials · doi:10.1002/adma.202102054 · Cited by 147 · see citing works
Role of Hedgehog Signaling in Breast Cancer: Pathogenesis and Therapeutics
Galdo, N. A. R., Montero, Á. L., & Wertheimer, E. V. (2019) · Cells · doi:10.3390/cells8040375 · Cited by 142 · see citing works
Chuang, L. I. U., Shin, J. W., Son, S., Choe, Y., Farokhzad, N., Tang, Z., Xiao, Y., Kong, N., Xie, T., Kim, J. S., et al. (2020) · Chemical Society Reviews · doi:10.1039/d0cs01175d · Cited by 141 · see citing works
Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Ferreira, R., Napoli, J., Enver, T., Bernardino, L., & Ferreira, L. (2020) · Nature Communications · doi:10.1038/s41467-020-18042-2 · Cited by 138 · see citing works
Arsenic in medicine: past, present and future
Paul, N. P., Galván, A. E., Yoshinaga-Sakurai, K., Rosen, B. P., & Yoshinaga, M. (2022) · BioMetals · doi:10.1007/s10534-022-00371-y · Cited by 120 · see citing works
Liang, C., Qiao, G., Liu, Y., Tian, L., Hui, N., Li, J., Ma, Y., Han, L., Zhao, Q., Cao, W., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113451 · Cited by 121 · see citing works
Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m6A signaling
Sun, K., Du, Y., Hou, Y., Zhao, M., Li, J., Du, Y., Zhang, L., Chen, C., Yang, H., Yan, F., et al. (2021) · Theranostics · doi:10.7150/thno.55574 · Cited by 109 · see citing works
Self-citationMolecular crosstalk between cancer and neurodegenerative diseases
Seo, J., & Park, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03428-3 · Cited by 106 · see citing works
Current Trends in ATRA Delivery for Cancer Therapy
Giuli, M. V., Hanieh, P. N., Giuliani, E., Rinaldi, F., Marianecci, C., Screpanti, I., Checquolo, S., & Carafa, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080707 · Cited by 92 · see citing works
Identification of a potent and selective covalent Pin1 inhibitor
Pinch, B. J., Doctor, Z. M., Nabet, B., Browne, C. M., Seo, H., Mohardt, M. L., Kozono, S., Lian, X., Manz, T. D., Chun, Y., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0550-9 · Cited by 90 · see citing works
Self-citationSteel, T. R., Walsh, F. P., Wieczorek, A., Hanif, M., & Hartinger, C. G. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213890 · Cited by 79 · see citing works
PIN1 in Cell Cycle Control and Cancer
Cheng, C.-W., & Tse, E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01367 · Cited by 65 · see citing works
Jiang, Y., Shen, X., Zhi, F., Wen, Z., Gao, Y., Xu, J., Yang, B., & Bai, Y. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01558-z · Cited by 63 · see citing works
Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer’s Disease
Chen, D., Zhou, X. Z., & Lee, T. H. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666181218170257 · Cited by 61 · see citing works
Self-citationSelf-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy
Zhai, Y., Liu, M., Yang, T., Luo, J., Wei, C., Shen, J., Xue, S., Ke, H., Sun, P., Guo, M., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.054 · Cited by 59 · see citing works
Classic and Variants APLs, as Viewed from a Therapy Response
Geoffroy, M., & de Thé, H. (2020) · Cancers · doi:10.3390/cancers12040967 · Cited by 57 · see citing works
Wang, Y., Chen, Y., Zhang, H., Chen, J., Cao, J., Chen, N., Li, X., & Sun, C. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111811 · Cited by 51 · see citing works
Self-citationSulfamate Acetamides as Self-Immolative Electrophiles for Covalent Ligand-Directed Release Chemistry
Reddi, R. N., Rogel, A., Gabizon, R., Rawale, D. G., Harish, B., Marom, S., Tivon, B., Arbel, Y. S., Gurwicz, N., Oren, R., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08853 · Cited by 49 · see citing works
Arsenic trioxide targets Hsp60, triggering degradation of p53 and survivin
Hu, X., Li, H., Ip, T. K.-Y., Cheung, H. Y. F., Koohi‐Moghadam, M., Wang, H., Yang, X., Tritton, D. N., Wang, Y., Wang, Y., et al. (2021) · Chemical Science · doi:10.1039/d1sc03119h · Cited by 49 · see citing works
Prolyl Isomerase Pin1 in Human Cancer: Function, Mechanism, and Significance
Pu, W., Zheng, Y., & Peng, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00168 · Cited by 46 · see citing works
Retinoids in hematology: a timely revival?
Geoffroy, M., Esnault, C., & de Thé, H. (2021) · Blood · doi:10.1182/blood.2020010100 · Cited by 46 · see citing works
Zhu, Q., Liang, P., Meng, H., Li, F., Miao, W., Chu, C., Wang, W., Li, D., Chen, C., Shi, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44349-x · Cited by 44 · see citing works
Self-citationFLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias
Esnault, C., Rahmé, R., Rice, K. L., Berthier, C., Gaillard, C. M., Quentin, S., Maubert, A.-L., Kogan, S. C., & de Thé, H. (2019) · Blood · doi:10.1182/blood-2018-07-866095 · Cited by 44 · see citing works
Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies
Wu, W., Xue, X., Chen, Y., Zheng, N., & Wang, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106456 · Cited by 43 · see citing works
Self-citationZhao, Y., Zang, G., Yin, T., Ma, X., Zhou, L., Wu, L. J., Daniel, R. A., Wang, Y., Qiu, J., & Wang, G. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.08.018 · Cited by 43 · see citing works
Luo, M., Zheng, F., Chen, W., Liang, Z.-M., Chandramouly, G., Tan, J., Willis, N. A., Chen, C.-H., Taveira, M. D. O., Zhou, X. Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2739 · Cited by 42 · see citing works
Self-citationVulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
Mugoni, V., Panella, R., Cheloni, G., Chen, M., Pozdnyakova, O., Stroopinsky, D., Guarnerio, J., Monteleone, E., Lee, J. D., Mendez, L., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0162-7 · Cited by 41 · see citing works
Yang, L., Li, J., Zang, G., Song, S., Sun, Z., Li, X., Li, Y., Xie, Z., Zhang, G., Gui, N., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10375 · Cited by 39 · see citing works
Zhang, A., Tao, W., Zhai, K., Fang, X., Huang, Z., Yu, J. S., Sloan, A. E., Rich, J. N., Zhou, W., & Bao, S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa150 · Cited by 39 · see citing works
Yang, Y., Li, Y., Li, R., & Wang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1338725 · Cited by 39 · see citing works
Retinoic acid signaling in development and differentiation commitment and its regulatory topology
Wu, D., Khan, F. A., Zhang, K., Pandupuspitasari, N. S., Negara, W., Guan, K., Sun, F., & Huang, C. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110773 · Cited by 37 · see citing works
Li, J., Wang, X., Guo, Y., Zhang, Y., Zhu, A., Zeng, W., Di, L., & Wang, R. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.144692 · Cited by 36 · see citing works
Oncogenic Hijacking of the PIN1 Signaling Network
Zannini, A., Rustighi, A., Campaner, E., & Sal, G. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00094 · Cited by 35 · see citing works
Huang, S., Chen, Y., Liang, Z.-M., Li, N., Liu, Y., Zhu, Y., Liao, D., Zhou, X. Z., Lu, K. P., Yao, Y., et al. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00322 · Cited by 35 · see citing works
Self-citationLiu, Y., Yu, F., Dai, S., Meng, T., Zhu, Y., Qiu, G., Wen, L., Zhou, X., Yuan, H., & Hu, F. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00220 · Cited by 35 · see citing works
Self-citationChang, K., Yin, J.-Z., Huang, H., Li, B., & Yang, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-467 · Cited by 34 · see citing works
Saeed, U., & Piracha, Z. Z. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.921653 · Cited by 33 · see citing works
Targeting Pin1 for Modulation of Cell Motility and Cancer Therapy
Chuang, H.-H., Zhen, Y., Tsai, Y.-C., Chuang, C., Huang, M., Hsiao, M., & Yang, C. (2021) · Biomedicines · doi:10.3390/biomedicines9040359 · Cited by 33 · see citing works
Zhang, Z., Yu, W.-X., Zheng, M., Liao, X., Wang, J., Yang, D., Lu, W., Wang, L., Zhang, S., Liu, H., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0656 · Cited by 30 · see citing works
Self-citationRoles of peptidyl-prolyl isomerase Pin1 in disease pathogenesis
Li, J., Mo, C., Guo, Y., Zhang, B., Feng, X., Si, Q., Wu, X., Zhao, Z., Gong, L., He, D., et al. (2021) · Theranostics · doi:10.7150/thno.45889 · Cited by 29 · see citing works
Development of Pin1 Inhibitors and their Potential as Therapeutic Agents
Nakatsu, Y., Matsunaga, Y., Ueda, K., Yamamotoya, T., Inoue, Y., Inoue, M.-K., Mizuno, Y., Kushiyama, A., Ono, H., Fujishiro, M., et al. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181105120911 · Cited by 28 · see citing works
Targeting Protein Folding: A Novel Approach for the Treatment of Pathogenic Bacteria
Scheuplein, N. J., Bzdyl, N. M., Kibble, E. A., Lohr, T., Holzgrabe, U., & Sarkar‐Tyson, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00911 · Cited by 27 · see citing works
Ueda, K., Nakatsu, Y., Yamamotoya, T., Ono, H., Inoue, Y., Inoue, M., Mizuno, Y., Matsunaga, Y., Kushiyama, A., Sakoda, H., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26691 · Cited by 25 · see citing works
Zhang, K., Lin, H., Mao, J., Luo, X., Wei, R., Su, Z., Zhou, B., Li, D., Gao, J., & Shan, H. (2019) · Biomaterials Science · doi:10.1039/c9bm00216b · Cited by 25 · see citing works
Song, Z., Zhang, J., Xu, Q., Shi, D., Yao, X., & Fang, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01441 · Cited by 24 · see citing works
He, S., Li, L., Jin, R., & Lu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00390 · Cited by 24 · see citing works
Targeting PIN1 as a Therapeutic Approach for Hepatocellular Carcinoma
Cheng, C.-W., & Tse, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00369 · Cited by 24 · see citing works
Liu, L., Zhu, R., Li, J., Pei, Y., Wang, S., Xu, P., Wang, M., Wen, Y., Zhang, H., Du, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01686 · Cited by 23 · see citing works
Post-translational Modifications of the Peptidyl-Prolyl Isomerase Pin1
Chen, D., Wang, L., & Lee, T. H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00129 · Cited by 23 · see citing works
Su, Y., Li, Z., Li, Q., Guo, X., Zhang, H., Li, Y., Meng, Z., Huang, S., & Hu, Z. (2024) · Theranostics · doi:10.7150/thno.99633 · Cited by 22 · see citing works
Engineering 2D Arsenic‐Phosphorus Theranostic Nanosheets
Hu, R., Dai, C., Wang, C., Lin, J., Hu, H., Li, Z., Lin, H., Ding, L., Chen, Y., & Zhang, B. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202101660 · Cited by 22 · see citing works
Self-citationChallenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs
Poetsch, I., Baier, D., Keppler, B. K., & Berger, W. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016452-00308 · Cited by 22 · see citing works
Chen, C., Li, Q., Xing, L., Zhou, M., Luo, C., Li, S., Li, L., & Huang, Y. (2021) · Nano Research · doi:10.1007/s12274-021-3923-9 · Cited by 21 · see citing works
Self-citationDiscovery of potent PROTAC degraders of Pin1 for the treatment of acute myeloid leukemia
Shi, Y., Liu, M., Li, M., Mao, Y., Ma, J., Long, R., Xu, M., Yang, Y., Wang, W., Zhou, Y., et al. (2024) · Chemical Science · doi:10.1039/d3sc06558h · Cited by 21 · see citing works
Yan, J., Hanif, S., Zhang, D., Ismail, M., Wang, X., Li, Q., Shi, B., Muhammad, P., & Wu, H. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c12076 · Cited by 20 · see citing works
Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy
Zhang, M., Gao, L., Ye, Y., & Li, X. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01187-2 · Cited by 19 · see citing works
The relevance of arsenic speciation analysis in health & medicine
Virk, R. K., Garla, R., Kaushal, N., Bansal, M. P., Garg, M. L., & Mohanty, B. P. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.137735 · Cited by 19 · see citing works
PIN1 and CDK1 cooperatively govern pVHL stability and suppressive functions
Chen, J., Li, M., Liu, Y., Guan, T., Yang, X., Wen, Y., Zhu, Y., Xiao, Z., Shen, X., Zhang, H., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01128-x · Cited by 18 · see citing works
Mutual promotion of co-condensation of KRAS G-quadruplex and a well-folded protein HMGB1
Wang, Y., Cao, K., Zong, M., Yuan, S., Zhang, N., & Liu, Y. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad938 · Cited by 18 · see citing works
The regulatory role of Pin1 in neuronal death
Xiong, K., Wang, S., & Hu, X. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.341043 · Cited by 18 · see citing works
A Pin1/PML/P53 axis activated by retinoic acid in NPM-1c acute myeloid leukemia
Hleihel, R., Hajj, H. E., Wu, H.-C., Berthier, C., Zhu, H., Massoud, R., Chakhachiro, Z. I., El-Sabban, M. E., de Thé, H., & Bazarbachi, A. A. (2021) · Haematologica · doi:10.3324/haematol.2020.274878 · Cited by 17 · see citing works
Perspectives of TrxR1-based cancer therapies
Arnér, E. S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818606-0.00031-6 · Cited by 17 · see citing works
Du, L., Wang, X., Cui, G., & Xu, B. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115878 · Cited by 17 · see citing works
Integrin αvβ3 Receptor Overexpressing on Tumor-Targeted Positive MRI-Guided Chemotherapy
Khatik, R., Wang, Z., Zhi, D., Kiran, S., Dwivedi, P., Liang, G., Qiu, B., & Yang, Q. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b16648 · Cited by 16 · see citing works
Lee, J., & Levin, D. E. (2019) · Molecular Biology of the Cell · doi:10.1091/mbc.e19-04-0228 · Cited by 15 · see citing works
Guo, Y., Lu, Y., Yi-Yang, J., Hui-Nan, Q., Da, Q., Xin-Qi, W., Pei-Ye, S., Jin, X., Xu, W., Dong, Y., et al. (2020) · Aging and Disease · doi:10.14336/ad.2019.0415 · Cited by 14 · see citing works
ATRA promotes PD-L1 expression to control gastric cancer immune surveillance
Ma, Z., Ding, Y.-L., Jing, J., Du, L., Zhang, X.-Y., Liu, H., & He, P. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174822 · Cited by 14 · see citing works
Chin, L., Kumana, C. R., Kwong, Y., & Gill, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091945 · Cited by 14 · see citing works
Fang, S., Hu, C., Xu, L., Cui, J., Li, T., Gong, M., Wang, Y., He, Y., He, T., & Bi, Y. (2020) · PubMed Central · Cited by 14 · see citing works
Zhao, J., Yuan, X.-K., Luo, R.-Z., Wang, L., Gu, W., Yamane, D., & Feng, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107239 · Cited by 14 · see citing works
Li, L., Zhu, R., Zhou, H., Cui, C., Xiao, Y., Liu, Y., Yin, Y., Li, Y., Feng, R., Katz, J. P., et al. (2023) · Advanced Science · doi:10.1002/advs.202207458 · Cited by 13 · see citing works
Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry
Ke, S., Dang, F., Wang, L., Chen, J.-Y., Naik, M. T., Li, W., Thavamani, A., Kim, N., Naik, N. M., Sui, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47427-w · Cited by 15 · see citing works
Self-citationPin1-Catalyzed Conformation Changes Regulate Protein Ubiquitination and Degradation
Jeong, J., Usman, M., Li, Y., Zhou, X. Z., & Lu, K. P. (2024) · Cells · doi:10.3390/cells13090731 · Cited by 13 · see citing works
Self-citationShi, L., Lu, J., Xia, X., Liu, X., Li, H., Li, X., Zhu, J., Li, X., Sun, H., & Yang, X. (2024) · Chemical Science · doi:10.1039/d4sc01294a · Cited by 13 · see citing works
Xin, X. J., Zou, J., Zou, T., Shang, H., & Sun, L. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/8485670 · Cited by 13 · see citing works
Jin, M. L., Wu, L., Chen, S., Cai, R., Dai, Y., Yang, H., Tang, L., & Li, Y. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00330-x · Cited by 13 · see citing works
Zhao, Q. C., Dong, X., Zhu, C., Zhang, Y., Fang, C., Zhou, X., Zhang, K., & Zhou, H. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.145556 · Cited by 13 · see citing works
Self-citationRetinoic acid attenuates cardiac injury induced by hyperglycemia in pre- and post-delivery mice
Liu, Y., Zhao, J., Lü, M., Wang, H., & Tang, F. (2019) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0009 · Cited by 13 · see citing works
Yuan, S., Yang, X., Bremmer, A., Wang, Y., Li, S., Chen, Y., You, Y., & Hu, Q. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2507711122 · Cited by 12 · see citing works
Self-citationKim, K., Park, P., & Lee, J. H. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112780 · Cited by 12 · see citing works
Lee, Y. M., Teoh, D. E.-J., Yeung, K., & Liou, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.956071 · Cited by 11 · see citing works
Liu, Y., Yue, J., Ren, Z., He, M., Wang, A., Xie, J., Li, T., Liu, G., He, X., Ge, S., et al. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116798 · Cited by 11 · see citing works
Lu, K. P., & Zhou, X. Z. (2024) · Science Signaling · doi:10.1126/scisignal.adi8743 · Cited by 11 · see citing works
Self-citationThe Pin1-CaMKII-AMPA Receptor Axis Regulates Epileptic Susceptibility
Hou, X., Yang, F., Li, A., Zhao, D., Ma, N., Chen, L., Lin, S., Lin, Y., Wang, L., Yan, X., et al. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhab004 · Cited by 11 · see citing works
Self-citationMicroRNA–Gene Interactions Impacted by Toxic Metal(oid)s during EMT and Carcinogenesis
Tran, F., Lee, E., Cuddapah, S., Choi, B. H., & Dai, W. (2022) · Cancers · doi:10.3390/cancers14235818 · Cited by 11 · see citing works
Duan, X., Xu, W., Li, H., Wang, M., Wang, W., Lu, H., Zhang, Y., & Han, X. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s388077 · Cited by 11 · see citing works
Effect of arsenic trioxide on cervical cancer and its mechanisms
Zhang, L., Zhou, Y., Kong, J., Zhang, L., Yuan, M., Xian, S., Wang, Y., Cheng, Y., & Yang, X. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9299 · Cited by 11 · see citing works
Nayek, U., Acharya, S., & Salam, A. A. A. (2023) · RSC Advances · doi:10.1039/d3ra05987a · Cited by 10 · see citing works
Manoochehri, H., Farrokhnia, M., Sheykhhasan, M., Mahaki, H., & Tanzadehpanah, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34300 · Cited by 10 · see citing works
Metal Complexes as Drugs and Therapeutic Agents
Zhou, Y. Y., Ip, T. K.-Y., Zhang, Q., Li, H., & Sun, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102688-5.00018-0 · Cited by 10 · see citing works
Probing conformational transitions of PIN1 from L. major during chemical and thermal denaturation
Biswas, G., Ghosh, S., Raghuraman, H., & Banerjee, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.03.166 · Cited by 10 · see citing works
A bibliometric analysis of PIN1 and cell death
Zhang, J., Ni, S.-Y., Tan, Y.-T., Luo, J., & Wang, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1043725 · Cited by 10 · see citing works
Recent advances of Pin1 inhibitors as potential anticancer agents
Bai, Y., Yuan, Z., Yuan, S., & He, Z. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107171 · Cited by 9 · see citing works
Differential metabolism of arsenicals regulates Fps1-mediated arsenite transport
Lee, J., & Levin, D. E. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202109034 · Cited by 9 · see citing works
Wu, C., Sun, C., Liu, G., Qin, Y., Xue, X., Wu, X., Wang, Q., Liu, J., Ye, Z., Li, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.850155 · Cited by 9 · see citing works
Zhang, H., He, Z., Deng, P., Lu, M., Zhou, C., Yang, L., & Yu, Z. (2022) · Toxicology Research · doi:10.1093/toxres/tfac040 · Cited by 9 · see citing works
Critical Role of Aquaporins in Cancer: Focus on Hematological Malignancies
Allegra, A., Cicero, N., Mirabile, G., Cancemi, G., Tonacci, A., Musolino, C., & Gangemi, S. (2022) · Cancers · doi:10.3390/cancers14174182 · Cited by 9 · see citing works
- Authors
- Kozono, S., Lin, Y.-M., Seo, H.-S., Pinch, B., Lian, X., Qiu, C., Herbert, M. K., Chen, C.-H., Tan, L., Gao, Z. J., Massefski, W., Doctor, Z. M., Jackson, B. P., Chen, Y., Dhe-Paganon, S., Lu, K. P., & Zhou, X. Z.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Fujian Medical University (CN)
- Broad Institute (US)
- Dartmouth College (US)
- Corresponding author
- Lu, Kun Ping
- Zhou, Xiao Zhen
- ORCID
- Venue
- Nature Communications
- Published
- 2018-08-09
- Volume
- 9
- Issue
- 1
- Pages
- 3069-3069
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6085299
- OpenAlex
- W2886147882
- Cited by
- 168
- References
- 82
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 23 · 2023: 28 · 2022: 20 · 2021: 22 · 2020: 28 · 2019: 18 · 2018: 5
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | National Institutes of Health (R01CA167677, R01CA205153)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- arsenic trioxide, all-trans retinoic acid, Pin1, isomerase, drug synergy, AQP9, triple-negative breast cancer, cancer stem cells, acute promyelocytic leukemia, protein degradation, microRNA, patient-derived xenografts
- MeSH terms
- NIMA-Interacting Peptidylprolyl Isomerase, Arsenic Trioxide, Animals, Antineoplastic Agents, Female, Fibroblasts, Humans, Mice, Inbred BALB C, Neoplasm Transplantation, Neoplasms, Magnetic Resonance Spectroscopy, Tretinoin, Signal Transduction, Leukemia, Promyelocytic, Acute, Gene Expression Regulation, Neoplastic, Mice, Knockout, Gene Expression Profiling, Proteomics, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
